Invios
invIOs GmbH is an Austrian biotech company pioneering next-generation immuno-oncology therapies powered by its proprietary EPiC cell therapy platform. With breakthrough programs such as INV441, a first-in-class Cbl-b–silenced TIL therapy for glioblastoma, and INV451, an innovative multiplex mRNA CAR approach for solid tumors, invIOs is redefining the future of personalised cancer treatment. Supported by strong partnerships, advanced technologies like CellMo, and robust investor confidence, the company is rapidly advancing toward transformative clinical milestones.
